Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Home page Seeking Alpha - Power to Investors About Premium Explore Alpha Picks Home ...

Several other label expansion studies on Imfinzi are currently underway, targeting other cancer indications. Imfinzi remains a key revenue driver for AstraZeneca’s oncology portfolio.

AstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Imfinzi is already approved for unresectable ... Sales momentum for the drug is still good, however, fuelled by a lengthening list of indications in other cancers, including most recently primary ...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab ... and Bavencio have bladder cancer indications. In a statement, the big UK pharma ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Eli Lilly and Company today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), retatrutide, eloralintide and bimagrumab will be presented at ...

In the study, Imfinzi was administered in combination with chemotherapy ... The FDA suggested that in the future, perioperative studies across indications will require a three- or four-arm trial ...

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...